KemPharm/$ZVRA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About KemPharm

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Ticker

$ZVRA
Sector
Primary listing

Employees

59

KemPharm Metrics

BasicAdvanced
$501M
-
-$0.08
1.87
-

What the Analysts think about KemPharm

Analyst ratings (Buy, Hold, Sell) for KemPharm stock.

Bulls say / Bears say

Open-label extension data published July 16, 2025 show sustained efficacy and a favorable safety profile for MIPLYFFA® for up to seven years in over 270 NPC patients, highlighting long-term disease stability (GlobeNewswire )
Sale of a Rare Pediatric Disease Priority Review Voucher generated net proceeds of $148.3 million, raising liquidity to $217 million as of Mar. 31, 2025, extending the cash runway into 2029 and strengthening commercial and R&D plans (SEC 10-Q )
The Phase 3 DiSCOVER trial for celiprolol in Vascular Ehlers–Danlos Syndrome has enrolled 32 patients and benefits from both Orphan Drug and Breakthrough Therapy designations, speeding up regulatory review and expanding pipeline value (AInvest.com )
Under-adoption of OLPRUVA® has held back the UCD franchise—with only one new prescription and $300,000 in sales in Q2 2025, significantly missing consensus expectations (Investors.com )
Since launch in July 2023, OLPRUVA® has achieved just 28 total patient enrollment forms through Q1 2025 despite 78% payer coverage, highlighting ongoing commercial challenges (BioSpace )
Zevra’s lead position in NPC is under immediate threat: IntraBio’s AQNEURSA® received FDA approval within days of MIPLYFFA®, intensifying competition for pricing and prescribing (FiercePharma )
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.

KemPharm Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

KemPharm Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ZVRA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs